Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
JP Sevilla, Daria Burnes, Rehab Zakaria El Saie, Hammam Haridy, Matt Wasserman, Sarah Pugh, Johnna Perdrizet & David Bloom. (2022) Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Bruce Cm Wang, Nathorn Chaiyakunapruk, Shuiqing Zhu, Joseph B. Babigumira, Wesley Furnback, Ramaa Chitale, Amgad Gamil, Kun Zhao & Matt Wasserman. (2022) A systematic literature review of economic evaluations of pneumococcal conjugate vaccines in east and southeast Asia (2006-2019). Expert Review of Vaccines 21:7, pages 885-898.
Read now
Read now
Johnna Perdrizet, Raymond A. Farkouh, Emily K. Horn, Kyla Hayford, Heather L. Sings & Matt D. Wasserman. (2022) The broader impacts of otitis media and sequelae for informing economic evaluations of pneumococcal conjugate vaccines. Expert Review of Vaccines 21:4, pages 499-511.
Read now
Read now
Emily K Horn, Matt D Wasserman, Cassandra Hall-Murray, Heather L Sings, Ruth Chapman & Raymond A Farkouh. (2021) Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges. Expert Review of Vaccines 20:10, pages 1291-1309.
Read now
Read now
Matt Wasserman, Heather L Sings, Dylan Jones, Sarah Pugh, Margaret Moffatt & Raymond Farkouh. (2018) Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine. Expert Review of Vaccines 17:1, pages 71-78.
Read now
Read now
David Bin-Chia Wu, Craig Roberts, Vivian Wing Yan Lee, Li-Wen Hong, Kah Kee Tan, Vivienne Mak & Kenneth Kwing Chin Lee. (2016) Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. Human Vaccines & Immunotherapeutics 12:2, pages 403-416.
Read now
Read now
Nathalie Böhles, Nathalie Böhles, Kim Busch, Kim Busch, Michael Hensel & Michael Hensel. (2014) Vaccines against human diarrheal pathogens. Human Vaccines & Immunotherapeutics 10:6, pages 1522-1535.
Read now
Read now
Maarten J. Postma & Baudouin A. Standaert. (2013) Economics of vaccines revisited. Human Vaccines & Immunotherapeutics 9:5, pages 1139-1141.
Read now
Read now
Articles from other publishers (10)
Mélanie Drolet, Élodie Bénard, Mark Jit, Raymond Hutubessy & Marc Brisson. (2018) Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature. Value in Health 21:10, pages 1250-1258.
Crossref
Crossref
Canna Ghia, Matt Wasserman, Mark Fletcher, Ray Farkouh & Gautam Rambhad. (2018) Modeling Possible Inclusion of Pneumococcal Conjugate Vaccine into the National Immunization Program for Infants in India. Value in Health Regional Issues 15, pages 99-105.
Crossref
Crossref
Alexander Kuhlmann & J.-Matthias Graf von der Schulenburg. (2016) Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. The European Journal of Health Economics 18:3, pages 273-292.
Crossref
Crossref
Jailton Azevedo, Eder Silva dos Anjos, Soraia M. Cordeiro, Milena S. dos Santos, Eliane C. Escobar, Paulo R. Lobo, Maria da Gloria Carvalho, Mitermayer G. Reis, Joice N. Reis & Leila C. Campos. (2016) Genetic profiles and antimicrobial resistance of Streptococcus pneumoniae non-PCV10 serotype isolates recovered from meningitis cases in Salvador, Brazil. Journal of Medical Microbiology 65:10, pages 1164-1170.
Crossref
Crossref
Raymond A. Farkouh, Cassandra Hall-Murray, Rogier M. Klok, Betsy Hilton & Raul E. Isturiz. (2015) Comment on: “Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children”. Infectious Diseases and Therapy 4:2, pages 227-233.
Crossref
Crossref
David Bin-Chia Wu, Nathorn Chaiyakunapruk, Huey-Yi Chong & Philippe Beutels. (2015) Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006–2014). Vaccine 33:14, pages 1633-1658.
Crossref
Crossref
Elisabetta De Cao, Alessia Melegaro, Rogier Klok & Maarten Postma. (2014) Optimising Assessments of the Epidemiological Impact in the Netherlands of Paediatric Immunisation with 13-Valent Pneumococcal Conjugate Vaccine Using Dynamic Transmission Modelling. PLoS ONE 9:4, pages e89415.
Crossref
Crossref
Katelijne van de Vooren, Silvy Duranti, Alessandro Curto & Livio Garattini. (2013) Cost Effectiveness of the New Pneumococcal Vaccines: A Systematic Review of European Studies. PharmacoEconomics 32:1, pages 29-45.
Crossref
Crossref
Rogier M. Klok, Rose-Marie Lindkvist, Mats Ekelund, Raymond A. Farkouh & David R. Strutton. (2013) The authors respond:. Clinical Therapeutics 35:7, pages 1048-1050.
Crossref
Crossref
Rogier M. Klok, Rose-Marie Lindkvist, Mats Ekelund, Raymond A. Farkouh & David R. Strutton. (2013) Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden. Clinical Therapeutics 35:2, pages 119-134.
Crossref
Crossref